Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 226 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: thalidomide Clear all
Completed Phase 1 Interventional

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

NCT00062127
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, thalidomide, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00602641
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Prednisone, Quality-of-Life Assessment, Thalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
389
States / cities
Mobile, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 255 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
235
States / cities
Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational

International CIPN Assessment and Validation Study

NCT04633655
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Quality of Life
Interventions
outcome measures for CIPN testing
Other
Lead sponsor
University of Milano Bicocca
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290
View directory record Official record
Conditions
Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
Interventions
Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, Cytarabine, Temozolomide (TMZ), Irinotecan
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
Up to 19 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Withdrawn Phase 2 Interventional

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

NCT00112879
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
arsenic trioxide, ascorbic acid, dexamethasone, thalidomide, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, chemotherapy, drug resistance inhibition, growth factor antagonist therapy, non-specific immune-modulator therapy
Drug · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

NCT00792142
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Interventions
bortezomib, dexamethasone, melphalan, thalidomide, cytogenetic analysis, fluorescence in situ hybridization, laboratory biomarker analysis, questionnaire administration, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

NCT01125176
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
thalidomide, lenalidomide, rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

NCT07671534
View directory record Official record
Conditions
Solid Tumor Cancer
Interventions
Gemcitabine, Mitomycin C, Thalidomide
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

NCT00072163
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Myelofibrosis

NCT00015821
View directory record Official record
Conditions
Primary Myelofibrosis
Interventions
thalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

NCT00090870
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, GM-CSF, thalidomide
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

NCT01779167
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Thalidomide, Lenalidomide, Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse

NCT00083681
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Dexamethasone, Cytoxan, Etoposide, Cisplatin, G-CSF
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2010 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00114192
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

NCT00277017
View directory record Official record
Conditions
Kidney, Cancer
Interventions
5-Flourouracil, Interferon-a, IL-2 and Thalidomide
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

NCT00412542
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma
Interventions
Thalidomide, CPT-11, MRI Scan, Quantitative Sensory Tests (QST)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

NCT01548573
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

NCT00458705
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

NCT00075023
View directory record Official record
Conditions
Graft-versus-Host Disease, Stomatitis
Interventions
Thalidomide Gel, Placebo Gel
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

NCT01849783
View directory record Official record
Conditions
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide, bortezomib, thalidomide, melphalan, autologous stem cell transplant
Drug · Procedure
Lead sponsor
Margarida Magalhaes-Silverman
Other
Eligibility
65 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients

NCT01697839
View directory record Official record
Conditions
Multiple Myeloma, Peripheral Neuropathy
Interventions
Not listed
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Highland, California • West Hollywood, California • Hinsdale, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

NCT00083876
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2010 · Synced Oct 17, 2026, 5:14 AM EDT
Terminated Phase 3 Interventional Results available

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

NCT01659658
View directory record Official record
Conditions
Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions
IXAZOMIB, Dexamethasone, Melphalan, Cyclophosphamide, Thalidomide, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 17, 2026, 5:14 AM EDT